Syncona

We do this by creating, building, and scaling companies to turn exceptional science into transformational treatments for patients in areas of high unmet need.

We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams.

Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies, and deliver strong risk-adjusted returns to shareholders.

Commercializing exceptional science

We take a long-term approach to building leading life science companies, focusing on maximising value through the cycle. Our fundamental view is that value creation in life science comes by taking products into late development, product approval and in some cases beyond.

We focus on building companies that can achieve this, ideally with multiple products, through our strategy of founding companies around exceptional science with the ability to deliver dramatic efficacy, building globally leading healthcare businesses, and funding them ambitiously to build scale while maintaining significant ownership stakes to the point of product approval.  

Our strategic drivers underpin our strategy. These are themes which are core to what we do and enable us to deliver value over the long term.

Syncona is well positioned to benefit from emerging trends within life sciences and broader society.